These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36547963)

  • 1. Topical Dexamethasone as an Adjuvant to Mineralocorticoid Receptor Antagonists for the Treatment of Recalcitrant Central Serous Chorioretinopathy.
    Wong A; Zhu D; Li AS; Lee JG; Ferrone PJ
    Ophthalmic Surg Lasers Imaging Retina; 2022 Dec; 53(12):659-665. PubMed ID: 36547963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study.
    Rajesh B; Agrawal H; Peguda HK; Chhablani J
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
    Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
    Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
    Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
    Venkatesh R; Pereira A; Jain K; Yadav NK
    BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.
    Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP
    Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
    Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
    Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis.
    Zhang B; Chou Y; Zhao X; Yang J; Chen Y
    Int Ophthalmol; 2020 Nov; 40(11):2957-2967. PubMed ID: 32632615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
    Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
    Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
    [No Abstract]   [Full Text] [Related]  

  • 11. [Eplerenone treatment in chronic central serous chorioretinopathy].
    Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
    J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthreshold laser compared to oral spironolactone for the treatment of chronic central serous chorioretinopathy: a retrospective study.
    Mercuri S; D'Alterio FM; Gallo B; Raslan W; Gupta A; Khairat N; Corazza P; Younis S
    Int Ophthalmol; 2024 Mar; 44(1):131. PubMed ID: 38478131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
    Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
    Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
    Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
    Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should We Stop Treating Patients With Eplerenone for Chronic CSCR? Commentary on the VICI Trial.
    Daugirdas SP; Bheemidi AR; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):308-310. PubMed ID: 34185584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of eplerenone on choroidal blood flow changes during isometric exercise in patients with chronic central serous chorioretinopathy.
    Gallice M; Daruich A; Matet A; Mouvet V; Dirani A; Evequoz G; Geiser M; Behar Cohen F; Chiquet C
    Acta Ophthalmol; 2021 Dec; 99(8):e1375-e1381. PubMed ID: 33650207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
    Kapoor KG; Wagner AL
    Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
    Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
    Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.